All In MedTech

Device Trial Radar · NCT06685848

Comparison of Hemanext ONE® System and Conventional Red Blood Cell Transfusion

Multi-Center, Randomized, Controlled Cross-Over Study to Evaluate Safety and Effectiveness of Hypoxic RBCs Processed With the Hemanext ONE System vs Conventional RBCs in Patients With Transfusion-Dependent Haematological Malignancies

Last checked: Nov 20, 2026Latest source record: Aug 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

24

Planned (sponsor's estimate)

Start

Nov 29, 2024

Primary completion

May 2028

Study completion Aug 2028

Sponsor

Lead sponsor
HemanextNot on our public-company list
Sponsor type
Industry
First posted
Nov 13, 2024

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Crossover
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The overall objective of this study is to collect preliminary effectiveness and safety data on the transfusion of hypoxic RBCs, manufactured with the Hemanext ONE device, in patients with hematological malignancies. The Hemanext ONE device received CE mark in April 2021 and marketing authorization through the FDA De Novo process in September 2023.

Conditions

  • Hematologic Neoplasms

Interventions

  • Hemanext ONE systemDevice

    Hypoxic red blood cells

  • Conventional RBCsDevice

    Conventional manufactured Red blood cells

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of RBCs units per unit of timeTime frame: Through study completion, an average of 15 months

Locations

2 sites in 2 countries. Site status is shown where the registry gives one.

  • Duke University Health System

    Durham, North Carolina

  • Haukeland University Hospital

    Bergen, Norway

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.